Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2015-04-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656566.2015.1032249PMID 25861982
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Teneligliptin: expectations for its pleiotropic action

  2015cited by this paper
• Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.

  2015cited by this paper
• Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers

  2015cited by this paper
• A review of gliptins for 2014

  2015cited by this paper
• Evidence-based practice guideline for the treatment for diabetes in Japan 2013

  2015cited by this paper
• Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double‐blind, placebo‐controlled study with an open‐label, long‐term extension

  2014cited by this paper
• Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients

  2014cited by this paper
• The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors

  2014cited by this paper
• Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment

  2014cited by this paper
• Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes

  2014cited by this paper
• Add-On Treatment with Teneligliptin Ameliorates Glucose Fluctuations and Improves Glycemic Control Index in Japanese Patients with Type 2 Diabetes on Insulin Therapy

  2014cited by this paper
• Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?

  2014cited by this paper
• Remote Glucose Monitoring in Camp Setting Reduces the Risk of Prolonged Nocturnal Hypoglycemia

  2014cited by this paper
• Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans

  2014cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

  2013influential reference
• Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus

  2013cited by this paper
• Efficacy, safety and dose–response relationship of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2 diabetes mellitus

  2013cited by this paper
• Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction

  2013cited by this paper
• Pharmacokinetics of Teneligliptin in Subjects With Renal Impairment

  2013cited by this paper
• Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

  2013cited by this paper
• A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site.

  2013cited by this paper
• Teneligliptin for the treatment of type 2 diabetes.

  2013cited by this paper
• The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes.

  2012cited by this paper
• Effects of once‐daily teneligliptin on 24‐h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4‐week, randomized, double‐blind, placebo‐controlled trial

  2012cited by this paper
• Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis

  2012cited by this paper
• The role of gut hormones in glucose homeostasis.

  2007cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper

• Proline, a privileged fragment in drug design: advances and future perspectives.

  2026cites this paper
• Review on Method Development and Validation of Remogliflozin Etabonate and Teneligliptin by RP-HPLC and UV Spectroscopy

  2025influential citation
• Protocol for a randomized controlled study comparing the efficacy and safety of daily versus alternate day teneligliptin 20 mg in type 2 diabetes mellitus patients

  2025cites this paper
• RENAL FUNCTION AND HYPOGLYCEMIC EVENTS WITH TENELIGLIPTIN VERSUS VILDAGLIPTIN IN DIABETIC PATIENTS: A PROSPECTIVE OBSERVATIONAL STUDY

  2023cites this paper
• Teneligliptin, a DPP-4 Inhibitor, Improves Vascular Endothelial Function via Divergent Actions Including Changes in Circulating Endothelial Progenitor Cells.

  2023cites this paper
• Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan

  2022cites this paper
• Potential approaches using teneligliptin for the treatment of type 2 diabetes mellitus: current status and future prospects

  2022cites this paper
• Teneligliptin versus vildagliptin in Indian patients with type 2 diabetes inadequately controlled with metformin

  2022cites this paper
• Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study

  2021cites this paper
• Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes

  2021cites this paper
• Indian Expert Review on Use of Teneligliptin in patients with Diabetes and its Safety and Efficacy (INTENSE).

  2021cites this paper
• Comparison of Efficacy between Dipeptidyl Peptidase-4 Inhibitor and Sodium-Glucose Cotransporter 2 Inhibitor on Metabolic Risk Factors in Japanese Patients with Type 2 Diabetes Mellitus: Results from the CANTABILE Study.

  2021cites this paper
• Is Teneligliptin Safe in Patients with Diabetes Mellitus Mainly with Reference to QT Prolongation

  2020cites this paper
• Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan

  2020cites this paper
• Glycemic and Non-Glycemic Effects of Teneligliptin

  2020cites this paper
• Efficacy and Safety of Teneligliptin as Add on Therapy in Indian Type 2 Diabetes Mellitus T2DM Patients Having Dyslipidemia

  2020cites this paper
• Effect of teneligliptin vs metformin on glycemic control in Indian patients with newly-diagnosed, drug-naïve type 2 diabetes mellitus: a 12-week randomized comparative clinical study

  2019cites this paper
• QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study)

  2019cites this paper
• The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice

  2019cites this paper
• Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T)

  2019cites this paper
• Rationale and Design of the CANONICAL Study　― Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Canagliflozin for Heart Failure With Preserved Ejection Fraction With Type 2 Diabetes Mellitus ―

  2019cites this paper
• A ProspectIve, OpeN-Label, Randomized Study Comparing EffIcacy and Safety of Teneligliptin VErsus Sitagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: INSITES Study.

  2019cites this paper
• Safety of T eneligliptin V E rsus S itagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus : INSITES Study

  2019cites this paper
• Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan

  2019cites this paper
• DMSO_A_202458 961..967

  2019cites this paper
• Title Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes

  2019cites this paper
• An Open Label, 2 Year Long Term Follow-Up Study to Assess the Efficacy, Safety and Tolerability of Teneligliptin in Indian Subjects with Type 2 Diabetes Mellitus

  2018cites this paper
• Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies

  2018cites this paper
• Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance

  2018cites this paper
• Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients

  2018cites this paper
• Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus

  2018cites this paper
• Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period

  2017influential citation
• Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group comparative study

  2017cites this paper
• DPP-4 Inhibitors

  2017cites this paper
• Long‐term safety and efficacy of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes

  2017cites this paper
• Efficacy and safety of teneligliptin

  2017cites this paper
• Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes

  2017cites this paper
• Teneligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions

  2017cites this paper
• Teneligliptin: Heralding Change in Type 2 Diabetes

  2016cites this paper
• DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects

  2016cites this paper
• The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension

  2016cites this paper
• Teneligliptin in type 2 diabetes: a guide to its use in Argentina

  2016influential citation
• The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory

  2016cites this paper
• Teneligliptin in type 2 diabetes: a guide to its use in Argentina

  2016cites this paper
• Teneligliptin: A Review in Type 2 Diabetes

  2015influential citation
• Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes

  2015cites this paper